ST
STE.US STERIS plc
- Market cap
- USD 25.0B
- P/E
- 31.1x
- P/B
- 3.50x
- ROE
- 11.4%
- Dividend yield
- 0.97%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is STE.US undervalued?
Graham numberSTE.US trades 119.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
STERIS plc fundamental analysis
No fundamental analysis for STERIS plc yet.
STERIS plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About STERIS plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment use…
Full company profileSTERIS plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
STERIS plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.61B | 2.62B | 2.78B | 3.03B | 3.11B | 4.22B | 4.54B | 5.14B | 5.46B | 5.94B | 6.16B |
| Gross Profit | 1.03B | 1.09B | 1.17B | 1.32B | 1.34B | 1.88B | 1.98B | 2.22B | 2.40B | 2.63B | 2.79B |
| Operating Income | 226M | 400M | 411M | 537M | 548M | 478M | 791M | 836M | 867M | 1.10B | 1.16B |
| EBITDA | 417M | 584M | 640M | 736M | 774M | 1.01B | 1.36B | 1.41B | 1.36B | 1.59B | 1.41B |
| Net Income | 110M | 291M | 304M | 408M | 397M | 244M | 107M | 378M | 615M | 785M | 828M |
| EPS | 1.28 | 3.39 | 3.56 | 4.76 | 4.63 | 2.48 | 1.07 | 3.81 | 6.20 | 7.95 | 8.48 |
| Balance Sheet | |||||||||||
| Total Assets | 4.92B | 5.20B | 5.07B | 5.43B | 6.57B | 11.4B | 10.8B | 11.1B | 10.1B | 10.7B | 10.7B |
| Total Liabilities | 2.11B | 1.98B | 1.89B | 2.02B | 2.68B | 4.88B | 4.73B | 4.75B | 3.53B | 3.54B | 3.44B |
| Shareholders' Equity | 2.81B | 3.22B | 3.19B | 3.41B | 3.89B | 6.53B | 6.09B | 6.30B | 6.60B | 7.18B | 7.26B |
| Cash & Short-term Investments | 283M | 202M | 221M | 320M | 221M | 348M | 208M | 207M | 172M | 440M | 531M |
| Total Debt | 1.55B | 1.39B | 1.24B | 1.17B | 1.67B | 3.28B | 3.11B | 3.38B | 2.20B | 2.09B | 2.05B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 424M | 458M | 540M | 591M | 690M | 685M | 757M | 973M | 1.15B | 1.34B | 1.31B |
| Capital Expenditure | 173M | 165M | 190M | 215M | 239M | 288M | 362M | 360M | 370M | 369M | 327M |
| Free Cash Flow | 251M | 292M | 350M | 376M | 450M | 397M | 395M | 613M | 778M | 972M | 985M |
| Ratios | |||||||||||
| ROE | 3.9% | 9.0% | 9.5% | 12.0% | 10.2% | 3.7% | 1.8% | 6.0% | 9.3% | 10.9% | 11.4% |
| ROA | 2.2% | 5.6% | 6.0% | 7.5% | 6.0% | 2.1% | 1.0% | 3.4% | 6.1% | 7.3% | 7.7% |
| Net Profit Margin | 4.2% | 11.1% | 10.9% | 13.5% | 12.8% | 5.8% | 2.4% | 7.4% | 11.3% | 13.2% | 13.4% |
| Debt to Equity | 0.55x | 0.43x | 0.39x | 0.34x | 0.43x | 0.50x | 0.51x | 0.54x | 0.33x | 0.29x | 0.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
STERIS plc dividends
- Dividend yield
- 0.97%
- Forward dividend
- 2.76 USD
- Payout ratio
- 30.8%
- Ex-dividend date
- Nov 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 242M | 2.45 | 30.8% |
| 2025 | USD 220M | 2.22 | 35.8% |
| 2024 | USD 201M | 2.02 | 53.0% |
| 2023 | USD 183M | 1.83 | 171.4% |
| 2022 | USD 163M | 1.66 | 66.9% |
| 2021 | USD 134M | 1.56 | 33.7% |
| 2020 | USD 123M | 1.44 | 30.2% |
| 2019 | USD 113M | 1.32 | 37.0% |
| 2018 | USD 103M | 1.20 | 35.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Aug 25, 1998.
Who owns STERIS plc
- Insiders 0.31%
- Institutions 99.69%
- Public & others 0.00%
- Shares outstanding 97.1M
- Free float 96.7M
Top funds holding STE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.09M | 3.18% | -0.84% | Sep 2026 |
| Vanguard 500 Index Investor | 2.56M | 2.64% | -1.74% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 2.09M | 2.15% | -1.58% | Sep 2026 |
| iShares Core S&P 500 ETF | 1.30M | 1.34% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 1.27M | 1.30% | -0.47% | Sep 2026 |
| MS INVF Global Brands A | 1.21M | 1.24% | -6.76% | Jun 2026 |
| State Street® SPDR® S&P 500® ETF | 1.20M | 1.23% | -0.25% | Oct 2026 |
| Vanguard Health Care Inv | 1.10M | 1.13% | -2.30% | Sep 2026 |
| JHancock Disciplined Value Mid Cap I | 998K | 1.03% | 0.00% | Sep 2026 |
| Janus Henderson Enterprise D | 994K | 1.02% | 0.00% | Sep 2026 |
| Vanguard Windsor Investor Shares | 948K | 0.98% | -0.33% | Sep 2026 |
| Vanguard MStar Value Index Investor | 929K | 0.96% | -0.82% | Sep 2026 |
| Invesco S&P 500® Equal Weight ETF | 917K | 0.94% | +0.17% | Oct 2026 |
| MFS Mid Cap Value A | 716K | 0.74% | -0.80% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 713K | 0.73% | +0.88% | Oct 2026 |
| MFS Massachusetts Inv Gr Stk A | 670K | 0.69% | -0.69% | Sep 2026 |
| T. Rowe Price US Large-Cap Core | 651K | 0.67% | 0.00% | Sep 2026 |
| Orbis Global Equity Investor | 579K | 0.60% | 0.00% | Jun 2026 |
| State Street® SPDR® S&P® Dividend ETF | 565K | 0.58% | 0.00% | Oct 2026 |
| Vanguard Dividend Appreciation ETF | 552K | 0.57% | -0.64% | Sep 2026 |
Top institutions holding STE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 8.82M | 9.08% | -2.28% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.41M | 6.60% | +0.64% | Jun 2026 |
| State Street Corp | 5.07M | 5.22% | +1.62% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 5.00M | 5.15% | +1.05% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.95M | 4.07% | -10.11% | Jun 2026 |
| Massachusetts Financial Services Company | 3.80M | 3.91% | -5.22% | Jun 2026 |
| Wellington Management Company LLP | 3.50M | 3.61% | +21.91% | Jun 2026 |
| Orbis Allan Gray Ltd | 2.68M | 2.76% | +3.27% | Jun 2026 |
| Geode Capital Management, LLC | 2.62M | 2.69% | +1.32% | Jun 2026 |
| Generation Investment Management LLP | 2.28M | 2.35% | -1.20% | Jun 2026 |
| Mitsubishi UFJ Asset Management Co.,Ltd | 2.20M | 2.27% | +0.24% | Jun 2026 |
| Select Equity Group LP | 1.89M | 1.95% | -11.60% | Jun 2026 |
| Jupiter Topco LLC | 1.89M | 1.94% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.83M | 1.89% | +4.03% | Jun 2026 |
| Amvescap Plc. | 1.81M | 1.86% | +5.73% | Jun 2026 |
| Boston Partners Global Investors, Inc | 1.50M | 1.54% | +73.77% | Jun 2026 |
| AQR Capital Management LLC | 1.38M | 1.42% | +29.76% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.36M | 1.40% | +257.24% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.22M | 1.25% | +134.43% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.21M | 1.25% | +0.79% | Sep 2026 |
STERIS plc company profile
- Company name
- STERIS plc
- Ticker
- STE.US
- ISIN
- IE00BFY8C754
- Exchange
- USA Stocks
- Listed since
- Jun 1, 1992
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 17,937
- Fiscal year end
- March
- Address
- 5960 Heisley Road, Mentor, OH, United States, 44060
- Phone
- 440 354 2600
- Website
- steris.com
About STERIS plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
STERIS plc management
10- Mr. Daniel A. CarestioPresident, CEO & Director · born 1973
- Ms. Karen L. BurtonSenior VP, CFO & Chief Accounting Officer · born 1968
- Mr. John Adam ZangerleSenior VP, General Counsel & Secretary · born 1967
- Ms. Mary Clare FraserSVP & Chief Human Resources Officer · born 1970
- Mr. Cary L. MajorsSenior VP & President of Healthcare · born 1975
- Ms. Julie WinterVice President of Investor Relations & Corporate Communications
- Ms. Lindsey McGowanVP, Chief Compliance & Quality Officer
- Ms. Julia K. MadsenSenior VP & GM of Life Sciences · born 1965
- Mr. Andrew XilasSenior VP & GM of Dental · born 1965
- Mr. Kenneth E. KohlerSenior VP & GM of AST · born 1963